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Differential requirements for myeloid leukemia
IFN-γ conditioning determine graft-versus-leukemia
resistance and sensitivity
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and Warren D. Shlomchik2,5,6
Department of Medicine, Yale University School of Medicine, New Haven, Connecticut, USA. 2Department of Medicine, University of Pittsburgh School of Medicine, University of Pittsburgh Cancer Institute,
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Pittsburgh, Pennsylvania, USA. 3Department of Computational Systems Biology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. 4Department of Immunology, St. Jude Children’s Research Hospital,
Memphis Tennessee, USA. 5Department of Microbiology and Pathology, University of Iowa, Iowa City, Iowa, USA. 6Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut, USA.

The graft-versus-leukemia (GVL) effect in allogeneic hematopoietic stem cell transplantation (alloSCT) is potent against
chronic phase chronic myelogenous leukemia (CP-CML), but blast crisis CML (BC-CML) and acute myeloid leukemias (AML) are
GVL resistant. To understand GVL resistance, we studied GVL against mouse models of CP-CML, BC-CML, and AML generated
by the transduction of mouse BM with fusion cDNAs derived from human leukemias. Prior work has shown that CD4+ T cell–
mediated GVL against CP-CML and BC-CML required intact leukemia MHCII; however, stem cells from both leukemias were
MHCII negative. Here, we show that CP-CML, BC-CML, and AML stem cells upregulate MHCII in alloSCT recipients. Using genedeficient leukemias, we determined that BC-CML and AML MHC upregulation required IFN-γ stimulation, whereas
CP-CML MHC upregulation was independent of both the IFN-γ receptor (IFN-γR) and the IFN-α/β receptor IFNAR1.
Importantly, IFN-γR–deficient BC-CML and AML were completely resistant to CD4- and CD8-mediated GVL, whereas IFN-γR/
IFNAR1 double-deficient CP-CML was fully GVL sensitive. Mouse AML and BC-CML stem cells were MHCI+ without IFN-γ
stimulation, suggesting that IFN-γ sensitizes these leukemias to T cell killing by mechanisms other than MHC upregulation.
Our studies identify the requirement of IFN-γ stimulation as a mechanism for BC-CML and AML GVL resistance, whereas
independence from IFN-γ renders CP-CML more GVL sensitive, even with a lower-level alloimmune response.

Introduction

Allogeneic hematopoietic stem cell transplantation (alloSCT) is
the most successful and widely applied form of adoptive T cell
immunotherapy. Alloreactive αβ T cells in allografts can recognize and kill recipient leukemia cells, thereby mediating the
graft-versus-leukemia (GVL) effect (1). Unfortunately, alloreactive T cells also attack nonmalignant host tissues, causing graftversus-host disease (GVHD) (2–4). A longstanding and elusive
objective has been to develop approaches that preserve GVL
while minimizing GVHD. A second and arguably more important goal is to overcome GVL resistance, as relapse of malignant
neoplasms is the greatest single cause of post-transplantation
mortality (5). GVL resistance and sensitivity are not equal across
different types of hematopoietic malignancies. For example,
chronic phase chronic myelogenous leukemia (CP-CML) is
exquisitely GVL sensitive, whereas blast crisis CML (BC-CML)
is relatively GVL resistant, despite the two sharing a common
biology, in that both are reliant on breakpoint cluster region/
Abelson murine leukemia viral oncogene homolog 1 (BCR/ABL)
signaling (6–8). Acute myeloid leukemias (AML) and acute lymphoblastic leukemias are also relatively GVL resistant.
Conflict of interest: The authors have declared that no conflict of interest exists.
Submitted: November 30, 2015; Accepted: April 20, 2017.
Reference information: J Clin Invest. 2017;127(7):2765–2776.
https://doi.org/10.1172/JCI85736.

Because GVL resistance and sensitivity track with the
identity of the underlying neoplasm, we reasoned that they are
leukemia cell–intrinsic properties. To understand the mechanisms of GVL resistance, we used mouse models to evaluate
GVL against CP-CML (mCP-CML) and BC-CML (mBC-CML)
(9–11). mCP-CML is created via retroviral transfer of the
BCR-ABL fusion cDNA, the defining genetic abnormality of
CP-CML, into mouse BM cells (12, 13), whereas mBC-CML is
created via retroviral transfer of both BCR-ABL and nucleoporin
98–homeobox A9 (NUP98-HOXA9) fusion cDNAs (14, 15). The
NUP98-HOXA9 fusion is a second-hit translocation in BC-CML
that has also been identified in de novo AML (14–22), as have
NUP98 fusions with other class I HOX genes. mCP-CML and
mBC-CML are therefore excellent phenocopies and genocopies
of their human counterparts, have defined stem cell populations
(15, 23), and, importantly, are GVL sensitive and GVL resistant, respectively (11). A powerful advantage of this approach
is that, by transducing BM from gene-deficient mice, we can
create gene-deficient leukemias as a means to explore mechanisms of GVL resistance (10, 11, 24–26). Using these systems,
we found that GVL against mCP-CML and GVL against mBCCML share essential features: (a) both leukemias must express
ICAM1; (b) T cell killing mechanisms are highly redundant;
and (c) CD8+ and CD4+ T cell killing requires T cell receptor–
MHCI (TCR-MHCI) or TCR-MHCII interactions, respectively
(11, 24, 25). Paradoxically, however, despite the fact that
jci.org   Volume 127   Number 7   July 2017
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Figure 1. Expression of MHC molecules on mCP-CML
and mBC-CML LSCs increases in the alloimmune
environment, independently of cognate TCR-MHC
interactions. MHCII expression on WT and MHCII–/–
mBC-CML (A, left) or mCP-CML (A, right) LSCs harvested
from mice transplanted with leukemia cells but without
GVH-inducing T cells. (B) Irradiated B6 mice were
reconstituted with C3H.SW BM and CD4 or CD8 T cells
and either mBC-CML or mCP-CML. Mice were sacrificed
between days 10 and 14, and LSCs were analyzed for
MHCI and MHCII expression. Representative data from
at least 3 independent experiments are shown. (C)
Irradiated B6 mice were reconstituted with C3H.SW BM
with B6 B2m–/– mBC-CML (MHCI–) and C3H.SW CD8 cells;
B6 MHCII–/– mBC-CML (MHCII–) and C3H.SW CD4 cells;
or WT B6 mBC-CML and C3H.SW CD4 or CD8 cells. On
day 15 after BMT, splenocytes were harvested, and MHCI
and MHCII expression on mBC-CML LSCs was assessed.
Similar MHC upregulation was noted on LSCs harvested
from BM (data not shown). Data are representative of 3
independent experiments. (D) Mice were transplanted
as in C, except with B2m–/– or MHCII–/– mCP-CML cells.
MHC upregulation was also independent of TCR-MHC
interactions. (E) Irradiated BALB/c mice were reconstituted with B6 BM and B6 mCP-CML with no T cells
or with B6 CD4 or CD8 cells. MHCII and MHCI were
upregulated on splenic mCP-CML LSCs on day 15 after
BMT. Similar MHC upregulation was seen in BM LSCs
(data not shown). (F) MHCIIhi and MHCIIlo mBC-CML LSCs
from mice undergoing a GVHD response (C3H.SW→B6
model with GVH induced by CD4 cells) were sort purified
and transferred into sublethally irradiated B6 mice. Both
populations transferred disease (F, left panels). Progeny
of sorted MHCIIhi and MHCIIlo mBC-CML cells recovered
15 days after transfer were MHCIIlo (F, right panel). FMO,
fluorescence minus one.

MHCII-deficient mCP-CML and mBC-CML were completely
resistant to CD4-mediated GVL, WT mCP-CML and mBCCML leukemia stem cells (LSCs) expressed little to no surface
MHCII, as MHCII staining was similar in WT and MHCIIdeficient LSCs (11). Here, we report that expression of MHCII
and MHCI on mBC-CML and MHCII on mouse AML (mAML;
induced by transduction with the MLL-AF9 fusion cDNA) (27)
and mCP-CML LSCs is upregulated in the alloimmune environment. Upregulation of MHC on mBC-CML and mAML required
IFN-γ receptor (IFN-γR) stimulation, whereas MHC upregulation on mCP-CML LSCs was entirely independent of IFN-γR or
IFN-α/β (IFNAR1) signaling. Importantly, IFN-γR–deficient
(Ifngr–/–) mBC-CML and mAML were highly resistant to both
CD4- and CD8-mediated GVL, whereas Ifngr–/–, Ifngr–/– Ifnar1–/–,
and Stat1–/– Stat2–/– mCP-CML were fully GVL sensitive. Our data
further suggest that IFN-γ sensitizes myeloblastic leukemias to
GVL by mechanisms beyond simply upregulating MHC. The
differential requirements for IFN-γ stimulation at least in part
explain the exquisite GVL sensitivity of CP-CML and GVL resistance of myeloblastic leukemias and suggest a therapeutic strategy for overcoming the GVL resistance of myeloblastic leukemias.
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Results

MHCII and MHCI are upregulated on leukemia cells in a GVH environment. Although MHCII-/- mCP-CML and mBC-CML were
completely resistant to CD4-mediated GVL, staining for surface
MHCII on WT and MHCII-/- LSCs harvested from sublethally
irradiated syngeneic recipients or alloBMT recipients that did not
receive donor T cells was similar (ref. 11 and Figure 1A). To account
for the MHCII requirement in GVL, we hypothesized that surface
MHCII was upregulated in an alloimmune environment. To test
this, we analyzed mBC-CML and mCP-CML cells from mice with
or without an ongoing GVH response in the C3H.SW→B6 model. MHCII was upregulated on both mBC-CML LSCs (lineage–
[lin–]or CD11b –) (ref. 15 and data not shown) and mCP-CML LSCs
(lin–sca-1+c-kit+) (ref. 28 and Figure 1B) harvested from mice in
which GVH was induced by either CD4 or CD8 cells. We found
that MHCI was consistently upregulated on mBC-CML LSCs but
minimally and inconsistently so on mCP-CML LSCs (Figure 1B).
MHC upregulation does not require TCR-MHC interactions.
Because CD4-mediated GVL absolutely requires both mCP-CML
and mBC-CML to express MHCII (10, 11, 24), we reasoned that
MHCII upregulation would occur in the GVH environment inde-
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Figure 2. The IFN-γR on
mBC-CML cells is required for
GVH-induced MHC upregulation and effective CD4- and
CD8-mediated GVL, whereas
MHCII upregulation on mCP-CML
cells and GVL are independent
of both the IFN-γR and IFNAR1
and STAT1/STAT2. (A) Irradiated
B6 mice were reconstituted with
C3H.SW BM and B6 Ifngr–/–, B6
Ifnar1–/–, or control WT B6 mBCCML cells, with no C3H.SW T cells
or C3H.SW CD4 or CD8 cells. MHCI
and MHCII upregulation did not
occur on Ifngr–/– mBC-CML LSCs
but was intact on Ifnar1–/– LSCs.
(B) Mice were transplanted as in
A, except with B6 WT or Ifngr–/–
mCP-CML cells. MHCII upregulation was similar in WT and
gene-deficient mCP-CML LSCs.
Consistent with the upregulation data, IFN-γR mBC-CML was
resistant to CD4- and CD8-mediated GVL in the C3H.SW→B6
model (C) and to CD8-mediated
GVL in the BALB/c→B6 model
(D). In contrast, Ifngr–/– mCP-CML
(E), Ifnar1–/– mBC-CML (F), Ifngr–/–
Ifnar1–/– (double-KO [DKO]) mCPCML (G), and Stat1–/– Stat2–/–
mCP-CML (H) cells were GVL
sensitive. Experiments shown
in E–H were in the C3H.SW→B6
model. AR1, IFNAR1–/–. P < 0.006,
comparing any WT mBC-CML
or IFNAR mBC-CML CD4 or CD8
recipient group with its BM-alone
control; P < 0.002, comparing
any mCP-CML T cell recipient
group with its BM-alone control.
P values determined by 2-tailed
Mann-Whitney U test.

pendently of TCR interactions with MHC on mBC-CML or mCPCML LSCs. Consistent with this, donor CD8+ T cells induced
MHCII upregulation on MHCI-deficient (β-2-microglobulin–
deficient, referred to herein as B2m–/–) B6 mBC-CML and mCPCML, and CD4 cells induced MHCI upregulation on MHCIIdeficient B6 mBC-CML cells (Figure 1, C and D). To further investigate the requirement of TCR-MHC interactions for MHC upregulation, we asked whether donor-strain mCP-CML cells in mice
undergoing a GVH response would upregulate MHCII. Irradiated
BALB/c mice were reconstituted with B6 BM and B6 mCP-CML
cells, with or without B6 CD4 or CD8 cells. In this design, donor
T cells are activated by host BALB/c cells, but because the T cells
are syngeneic with the B6 mCP-CML, they do not mediate GVL
and presumably do not have high-avidity TCR-MHC interactions
with them. In line with data using MHC-deficient mCP-CML,
we observed that MHCII was upregulated on donor mCP-CML

LSCs in GVH mice relative to LSCs in mice that did not receive
donor T cells (Figure 1E).
MHCIIhi mBC-CML cells can serially transplant leukemia. To
determine whether LSC-phenotype cells induced to express
MHCII have functional properties of LSCs, we sort purified
MHCIIhiCD11b – and MHCIIloCD11b – mBC-CML cells from mice
undergoing a GVH response and transferred them into sublethally
irradiated syngeneic B6 mice. Both MHCIIlo and MHCIIhi mBCCML cells transferred mBC-CML, but the progeny of MHCIIhi
cells lost MHCII expression (Figure 1F), indicating that MHCII
upregulation was transient.
Role of IFNs in leukemia MHC upregulation and GVL. IFNs
upregulate MHC on many cell types. To test the role of IFNs
in GVH-induced MHC upregulation on mBC-CML cells, we
created type I IFN receptor–deficient (Ifnar1–/–) and IFN-γR–
deficient (Ifngr–/–) mBC-CML. Whereas MHC upregulation
jci.org   Volume 127   Number 7   July 2017
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Figure 3. IFN-γ stimulation is required for
TMH60-mediated GVL against H60+ mBC-CML
and CD4- and CD8-mediated GVL against
MLL-AF9–induced AML. (A–E). Irradiated
B6.H60 mice were reconstituted with C3H.
SW BM, WT or Ifngr–/– B6.H60 mBC-CML,
with no T cells or with and 5 × 104 sort-purified CD8+CD44+ cells from H60-vaccinated
donors, which contained 3,500 TetH60+
cells. (A) Post-transplantation survival. (B)
Representative TetH60 staining of blood CD8
cells from WT and Ifngr–/– H60+ mBC-CML
recipients and their quantitation (C) on day
14 after transplantation. The percentage
of blood NGFR+EGFP+ cells on day 14 after
transplantation and the percentage of
these cells that were MHCII+ are shown in
D and E, respectively. For C–E, each symbol
represents data from an individual mouse;
horizontal lines represent the mean.
P = 0.0034, comparing survival of recipients
of WT H60+ BC-CML, with or without TMH60.
P = 0.378, comparing survival of recipients
of Ifngr–/– H60+ mBC-CM with or without
TMH60. (F–H) Irradiated B6 mice were reconstituted with C3H.SW BM, WT or Ifngr–/–
MLL-AF9 AML with no T cells, or with C3H.
SW CD4 or CD8 cells. Spleen and BM cells
were harvested on day 13 after transplantation and analyzed for MLL-AF9 AML (GFP+)
MHCII expression (F). Survival for CD4-mediated and CD8-mediated GVL is shown in
G and H, respectively. P ≤ 0.0016, comparing
the survival in the WT mAML BM-alone
group with WT CD4 or CD8 recipients;
P = 0.024, comparing Ifngr–/– BM alone with
CD4 recipients; P = 0.0079 and P = 0.0053,
comparing CD4 and CD8 recipients of WT
versus Ifngr–/– MLL-AF9 AML, respectively.
P values determined by 2-tailed MannWhitney U test. Data in G and H were
combined from 2 repetitions.

was intact in Ifnar1–/– mBC-CML cells, we found that it was
completely abrogated in Ifngr–/– mBC-CML cells (Figure 2A).
In contrast, MHCII upregulation was similar in WT and Ifngr–/–
mCP-CML LSCs harvested from GVH mice (Figure 2B). Strikingly, consistent with the MHC upregulation data, Ifngr–/– mBCCML was completely resistant to CD4- and CD8-mediated
GVL in the C3H.SW→B6 strain pairing (Figure 2C), whereas
Ifnar1–/– mBC-CML, Ifngr–/– mCP-CML, Ifngr–/– Ifnar1–/–, and
Stat1–/– Stat2–/– mCP-CML were as GVL sensitive as their WT
counterparts (Figure 2, E–H). It was unexpected that Ifngr–/–
mBC-CML was completely resistant to CD8-mediated GVL as
there is substantial basal MHCI expression that is only modestly
increased with IFN-γ stimulation. We considered the possibility that there is a dominant, targeted minor histocompatibility
antigen (miHA) that depends on IFN-γ for its generation and
presentation. We therefore performed a GVL experiment in the
2768
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BALB/c (H-2d)→B6 MHC-mismatched system, in which it would
be unlikely that CD8 alloimmunity would rely on a single miHA.
Even with an MHCI mismatch, IFN-γR–/– mBC-CML was completely resistant to CD8-mediated GVL (Figure 2D), suggesting
that IFN-γ sensitization of mBC-CML cells to CD8-mediated
GVL involves more than MHCI upregulation.
We also compared the GVL effect against WT and Ifngr–/–
mBC-CML mediated by memory T cells raised against the miHA
H60 (26, 29, 30). C3H.SW mice (H60–) were vaccinated against
H60 as previously reported (26). B6.H60 mice (congenic for H60)
were irradiated and reconstituted with C3H.SW BM, with WT or
Ifngr–/– B6.H60 mBC-CML with no T cells, or with 5 × 104 sortpurified CD8+CD44+ cells from H60-vaccinated mice (TMH60)
containing 3,500 H60-reactive cells as determined by H60
tetramer staining (TetH60; data not shown). Ifngr–/– B6.H60 mBCCML was highly GVL resistant (Figure 3A, survival), despite an
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the effects of IFN-γ on mBC-CML cells
in vitro. Culture in media plus IFN-γ,
but not media alone, induced MHCII
upregulation. With continuous culture
in IFN-γ at concentrations detected in
the serum of GVHD mice (31), MHCII
upregulation was not detected until 24
to 48 hours and usually peaked between
48 and 72 hours (Figure 4A and data not
shown). An IFN-γ pulse of as short as 1
hour induced MHCII upregulation on a
minority of cells at 72 hours, but maximum MHCII upregulation required
exposure for 8 to 18 hours (Figure 4B).
Despite this requirement, in vitro IFN-γ
stimulation induced mBC-CML STAT1
phosphorylation within 15 minutes
(Figure 4C), indicating that, despite
rapid STAT1 phosphorylation, more
prolonged IFN-γR signaling is required
Figure 4. In vitro IFN-γ treatment is sufficient to upregulate MHCII on mBC-CML LSCs. (A) Sort-purified
mBC-CML LSCs were continuously cultured with graded concentrations of IFN-γ, and MHCII expression was
for maximal MHCII upregulation. To
measured 72 hours later. (B) mBC-CML LSCs were cultured for 30 minutes to 24 hours in IFN-γ (200 pg/ml).
determine whether the in vitro time
Stimulated cells were washed extensively and then further cultured without IFN-γ for a total culture time
course of MHCII upregulation paralof 72 hours, followed by measurement of MHCII expression. The final supernatant from each wash was
lels what occurs in vivo, we transferred
cultured with fresh mBC-CML cells for 72 hours, and MHCII was not upregulated (see “24-Hour wash superB6 MHCIIlo mBC-CML cells harvested
natant” in B). Data are representative of 2 experiments, with 3 replicates per condition. (C) mBC-CML cells
were cultured in IFN-γ, and p-STAT1 was measured by flow cytometry at the indicated times. (D) Irradiated
from sublethally irradiated syngeneic
B6 mice were reconstituted with C3H.SW BM with or without C3H.SW CD4 cells. On day 7 after alloBMT,
B6 mice into irradiated B6 mice that
sort-purified mBC-CML LSCs were injected. mBC-CML cells were recovered 48 and 96 hours later and MHCI
were transplanted with C3H.SW BM,
and MHCII expression was analyzed by flow cytometry. Shown are data from splenic mBC-CML cells; data
with or without C3H.SW CD4 cells, 7
in BM were similar (not shown). Each line represents data from an individual mouse. (E) Irradiated B6
days earlier. We observed that MHCI
mice were transplanted with mBC-CML cells, C3H.SW BM, and CD4 cells. On day 21 after transplantation,
sort-purified splenic MHCII– CD11b– mBC-CML cells were cultured with or without IFN-γ for 72 hours. IFN-γ
and MHCII expression increased
induced MHCII expression.
on splenic (Figure 4D) and BM (not
shown) mBC-CML LSCs in GVH mice
at 48 and 96 hours after transfer, but not in mice that did not
expansion of H60-reactive T cells in blood that was at least as
receive CD4 cells.
strong as that observed in recipients of WT B6.H60 mBC-CML
These results identify a key mechanism that at least in part
(Figure 3, B and C). Whereas TMH60 reduced blood WT B6.H60
explains the resistance of mBC-CML and AML GVL against GVL
mBC-CML cells, they failed to do the same against Ifngr–/– B6.H60
compared with the GVL that develops against CP-CML. Effective
mBC-CML (Figure 3D). Finally, H60-reactive CD8 cells induced
GVL against mBC-CML and mAML requires sufficient and susMHCII upregulation (a marker for IFN-γ stimulation) only on WT
tained IFN-γ to sensitize LSCs to T cell killing, whereas effective
B6.H60 mBC-CML cells (Figure 3E).
GVL against mCP-CML does not require IFN-γ stimulation . mBCTo determine whether the reliance on IFN-γ stimulation for
CML LSCs recovered from mice that were dying from leukemia
effective GVL is unique to mBC-CML or is a more general property
at later times after transplantation, despite being transplanted
of myeloblastic leukemias, we created WT and Ifngr–/– AML by transwith donor T cells, were mostly MHCIIlo. This decline in MHCII
ducing WT or Ifngr–/– BM with a retrovirus encoding the MLL-AF9
translocation (27) and then tested the sensitivities of these AML cells
expression was not due to selection for cells that could not respond
to CD4- and CD8-mediated GVL in the C3H.SWgB6 model. Cohorts
to IFN-γ, as MHCIIlo cells harvested from mice with progressive
were sacrificed 12 days after BMT for analysis of MHC expression
mBC-CML, despite receiving donor T cells, uniformly upregulated
on splenic and BM AML cells. CD4 and CD8 cells induced a modest
MHCII in vitro with IFN-γ stimulation (Figure 4E). This suggests
upregulation of MHCII on WT AML cells but not on Ifngr–/– AML cells
that leukemia progression at later points after transplantation is
due to both a contraction of the alloreactive T cell response and a
(Figure 3F). MHCI was not upregulated (date not shown). Importantdrop in IFN-γ levels.
ly, compared with WT MLL-AF9, we found that Ifngr–/– MLL-AF9
mBC-CML and mCP-CML gene expression changes in the GVH
mAML was relatively resistant to both CD4- and CD8-mediated GVL
environment. To better understand potential mechanisms of action
(Figure 3, G and H).
of IFN-γ, we performed gene expression analyses on WT and
IFN-γ is sufficient to upregulate MHC on mBC-CML cells. While
Ifngr–/– mBC-CML and WT mCP-CML LSCs sorted from mice
the IFN-γR was required for MHC upregulation on mBC-CML cells
in vivo, it was possible that other unidentified stimuli were also
that were or were not undergoing a GVH response. For mBC-CML
required. To test whether IFN-γ alone is sufficient, we examined
LSCs, irradiated B6 mice were reconstituted with WT or Ifngr–/–
jci.org   Volume 127   Number 7   July 2017
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Figure 5. Gene expression analyses of mBC-CML and mCP-CML LSCs. (A–D)
WT or Ifngr–/– mBC-CML cells were harvested from C3H.SW→B6 recipients
of C3H.SW CD4 cells. Shown are Gene Set Enrichment Analysis–style (GSEAstyle) barcode plots for IFN-γ pathway gene expression using hallmark data.
Note the significant upregulation of IFN-γR pathway genes comparing WT
mBC-CML cells harvested from CD4 recipients with WT mBC-CML LSCs from
BM-alone recipients (A), Ifngr–/– mBC-CML LSCs from CD4 recipients (B), and
Ifngr–/– mBC-CML LSCs from BM-alone recipients (C). There was no IFN-γR
signature comparing Ifngr–/– mBC-CML LSCs harvested from CD4 recipients
compared with those from BM-alone recipients (D), and few differentially
expressed genes distinguished these groups (Supplemental Figure 1). (E)
WT B6 mCP-CML LSCs were harvested from BALB/c recipients that did or
did not receive CD4 cells (BM alone). An IFN-γR signature was observed in
RNA from LSCs harvested from CD4 recipients as compared to RNA from
LSCs from BM alone controls.

2770
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mBC-CML cells, C3H.SW T cell–depleted BM, with or without
C3H.SW CD4 cells. For mCP-CML, to facilitate recovery of sufficient mCP-CML cells, we again used the B6gBALB/c GVH system with B6 mCP-CML cells, with or without B6 CD4 cells. mBCCML and LSK mCP-CML cells (lin–) were harvested between days
12 and 14 after BMT. LSCs from 3 individual mice were analyzed
from each group.
We saw a clear IFN-γ gene signature when comparing mRNA
from Ifngr–/– mBC-CML cells from the BM-alone group with mRNA
from WT mBC-CML cells harvested from CD4 recipients (Figure 5).
Relative to the Ifngr–/– groups, there was a background IFN-γ signature in WT mBC-CML cells harvested from the B6 BM-alone group,
probably due to IFN-γ produced by the host-versus-graft response.
In addition to a classic IFN-γ signature, in WT BC-CML cells from
GVH mice, we observed changes in genes linked to antigen presentation, ubiquitination, proteasome function, and apoptosis. As
expected, there was no IFN-γ signature in the IFN-γR mBC-CML
cells. By volcano plot analysis, we found that gene expression was
similar in Ifngr–/– mBC-CML LSCs harvested from the BM-alone
and CD4 groups, and pathway analyses were unrevealing as to what
drove the few observed differences (data not shown).
mCP-CML gene expression analysis. We also detected an IFN-γ
signature in mCP-CML LSCs harvested from CD4 recipients relative
to LSCs harvested from mice treated with BM alone (Supplemental
Figure 1; supplemental material available online with this article;
https://doi.org/10.1172/JCI85736DS1). Therefore, the fact that WT
mCP-CML and Ifngr–/– mCP-CML were equivalently GVL sensitive
was not due to WT mCP-CML being unresponsive to IFN-γ.
T cells are the critical source of IFN-γ. T cells are the major, but
not exclusive, producers of IFN-γ. To determine whether donor
T cell–derived IFN-γ is required for MHC upregulation and GVL,
we compared mBC-CML MHC upregulation and GVL in recipients of WT or IFN-γ–deficient CD4+ T cells. Because TCR-MHC
interactions were not required for MHC upregulation, we also
considered the possibility that T cells unable to directly kill leukemia cells could provide IFN-γ in trans, thereby rescuing the
inability of IFN-γ–deficient T cells to mediate GVL. Irradiated
B6 mice were reconstituted with B6 B2m–/– mBC-CML (MHCI–)
and BALB/c BM with: a) no T cells; b) WT or IFN-γ–deficient
BALB/c CD4 cells; or c) WT or IFN-γ–deficient CD4 cells with
WT or IFN-γ–deficient BALB/c CD8 cells. B2m–/– mBC-CML was
used to prevent donor CD8 cells from directly killing leukemia
cells. Whereas WT CD4 cells induced MHCII expression and
reduced the number of splenic and BM mBC-CML cells by day
14 after BMT, IFN-γ–deficient CD4 cells failed to do so (Figure 6,
A–C, and data not shown), indicating that donor T cell–derived
IFN-γ is critical. The addition of WT, but not IFN-γ–deficient,
CD8 cells restored IFN-γ–induced MHCII upregulation and
diminished the number of mBC-CML cells in spleen and BM
by day 14 (Figure 6, A–C, and not shown), indicative of a GVLpromoting effect. Consistent with this early GVL effect, the addition of WT, but not IFN-γ–deficient, CD8 cells to IFN-γ–deficient
CD4 cells prolonged the survival of mice in 2 of 3 repeated experiments (Figure 6D). The rescue of IFN-γ–deficient CD4 cells by
WT CD8 cells may have been incomplete because of differences
in the kinetics and magnitude of IFN-γ production by CD4 and
CD8 cells, which is consistent with the lower mean fluorescence

intensity (MFI) of MHCII in the IFN-γ–deficient CD4 plus WT
CD8 group (mean of 443 vs. 167). That the addition of WT CD8
cells to IFN-γ–deficient CD4 cells restored GVL also confirms
that the inability of IFN-γ–deficient CD4 cells to mediate GVL
was not due to a failure to generate cytolytic effectors.
IFN-γ alone is insufficient for GVL. Given the complete GVL
resistance of Ifngr–/– mBC-CML, we considered the possibility that
IFN-γ alone has direct and meaningful antileukemia activity. Arguing against this is that for effective GVL, CD4 and CD8 cells require
leukemia expression of MHCII and MHCI, respectively (10, 11, 24)
despite alloreactive T cells activated in response to recipient alloantigens generating substantial IFN-γ. However, sufficiently high
local IFN-γ levels may only be achieved when IFN-γ–producing T
cells make cognate TCR-MHC contacts. To test this hypothesis,
we engineered a situation in which cognate TCR-MHC interactions occurred, but perforin and death receptor–dependent T cell–
induced apoptosis and necroptosis were prevented. We first created Fas (TNFRSF6) via Fas-associated protein with death domain
(Fadd–/– Ripk3–/–) mBC-CML cells. FADD is required for all death
receptor signaling; however, Fadd–/– mice are embryonically lethal
unless they are crossed with Ripk3–/– mice due to the role of FADD
in inhibiting RIPK3-dependent necroptosis (32). We then compared
GVL mediated by WT or perforin–/– CD4 or CD8 cells against Fadd–/–
Ripk3–/– and control Fadd+/– Ripk3+/– mBC-CML. Effective GVL only
required either WT T cells or FADD/RIPK3-intact mBC-CML (Figure 7). In contrast, GVL was completely abrogated when donor T
cells were perforin–/– and mBC-CML cells were Fadd–/– Ripk3–/–,
despite T cells being capable of producing IFN-γ and making TCRMHC contacts with mBC-CML cells. Therefore, CD4- and CD8dependent GVL depends on T cell perforin and/or mBC-CML death
receptor signaling, and T cell–derived IFN-γ alone is insufficient.

Discussion

Relapsed acute leukemia after alloSCT remains a major unmet medical need. Much of the early and exciting efficacy of alloSCT as a form
of adoptive T cell immunotherapy was observed in patients with
CP-CML (33); however, in the tyrosine kinase inhibitor era, these
patients infrequently undergo transplantation. While GVL is active
against myeloblastic leukemias, it is less potent than GVL against
CP-CML. This difference in potency is reflected in the higher rates
of BC-CML and AML relapse after alloSCT. Unfortunately, there has
been little progress in decreasing or treating relapses, in which the
withdrawal of immunosuppression and donor leukocyte infusions
infrequently result in durable remissions. A major barrier to progress has been a lack of understanding of the resistance mechanisms.
A central paradox, evident since the early days of clinical alloSCT,
is why an alloimmune response sufficient to cause GVHD, promote
100% donor hematopoietic chimerism, and mediate GVL against
CP-CML is so much less effective against AML. Here, we report a
mechanism that may explain this: the alloimmune T cell response
against AML and BC-CML must generate sufficient IFN-γ to sensitize myeloblast LSCs to T cell killing. In contrast, a smaller and more
smoldering alloreactive response, which does not generate high levels of IFN-γ, is sufficient for GVL against mCP-CML and for GVHD.
Ifngr–/– mBC-CML and MLL-AF9 mAML were GVL resistant, and, conversely, IFN-γ–deficient T cells mediated no
GVL against mBC-CML, despite their expansion and induction
jci.org   Volume 127   Number 7   July 2017
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Figure 6. T cell–derived IFN-γ delivered in cis or in trans is required for CD4-mediated GVL. Irradiated B6 mice were reconstituted with BALB/c BM and B6
B2m–/– mBC-CML with no T cells or with the following BALB/c background T cells: (i) WT CD4 cells; (ii) IFN-γ–deficient CD4 cells; (iii) WT CD4 cells plus WT CD8
cells; (iv) IFN-γ–deficient CD4 cells plus WT CD8 cells; or (v) IFN-γ–deficient CD4 cells plus IFN-γ–deficient CD8 cells. Cohorts were sacrificed 10–14 days after
transplantation, and mBC-CML cells were analyzed by flow cytometry. (A) Representative flow cytometry from splenocytes. (B) Percentage of leukemic splenocytes from individual mice (n = 3 independent experiments). Each symbol represents data from an individual mouse; horizontal lines indicate mean values.
(C) Upper panel: WT, but not IFN-γ–deficient, CD4 or CD8 cells induced MHCII upregulation on mBC-CML LSCs. The upper panel shows LSC MHCII expression.
Each line represents data from an individual mouse. Lower panel: Percentage of LSCs that were MHCII+ from 2 of 3 experiments. Each symbol represents
data from an individual mouse; horizontal lines indicate the mean values. Insufficient numbers of LSCs were present to analyze in the third experiment (see
bottom panel in Figure 5B). (D) In 2 of 3 experiments, the addition of WT CD8 cells, but not IFN-γ–deficient CD8 cells, to IFN-γ–deficient CD4 cells prolonged
survival (data were combined from 2 experiments). P = 0.0037 comparing the KO CD4 + WT CD8 group to either the KO CD4 or KO CD4 + KO CD8 groups.

of clinical GVHD (data not shown). In mouse models without
immunosuppression, there is an early wave of IFN-γ production coincident with rapid alloreactive T cell expansion (34–36).
However, in clinical alloSCT, in which pharmacologic immunosuppression is given, such a rise in IFN-γ may only infrequently
occur, and this may in part contribute to the more global GVL
resistance of myeloblastic leukemias. Chronic GVHD (cGVHD)
has been associated with a lower risk for AML relapse, and
recent data suggest that cGVHD is associated with the action of
IFN-γ (37). Perhaps the sustained IFN-γ associated with cGVHD
contributes to GVL, along with alloreactive cytolytic T cells. In
contrast, GVL against mCP-CML was independent of type I and
II IFNs or their downstream signaling components STAT1 and
2772
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STAT2, even though gene expression analysis indicated that
mCP-CML LSCs are IFN-γ responsive.
In an effort to understand the cell-intrinsic properties of mBCCML cells that render them GVL resistant relative to CP-CML cells,
we have tested in GVL models mouse blast crisis and chronic phase
leukemias deficient in numerous genes including those encoding
β2M, MHCII, Fas, TRAIL, TNFR1/R2, PD-L1, PD-L2, ICAM-1, and
IFNAR1 (10, 11, 24, 25). Until the present study, we found no deficiency that selectively diminished GVL against mBC-CML without
equivalently reducing GVL against mCP-CML.
Other factors in addition to the requirement for IFN-γR signaling may also contribute to the relative GVL resistance of myeloblastic leukemias as compared with that of CP-CML. Nonetheless, the
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of T cells that recognize allogeneic MHC (46, 47)
and the diminished likelihood that GVL in this
model would rely on a single targeted peptide.
IFN-γ upregulates ICAM-1 (data not shown),
immunoproteasome components, and chemokines that attract T cells and modifies pro- and
antiapoptotic pathways (Figure 5 and ref. 48), all
of which could promote effective CD8 cell killing. Discovering precisely how IFN-γR signaling
sensitizes mBC-CML and AML cells to killing
will require substantial further investigation, and
given the pleiotropic effects of IFN-γR signaling,
it is possible that no single downstream mechanism will explain its dominant role. Another
intriguing and unanswered question is what signal(s) in the alloimmune environment induce
MHCII upregulation on mCP-CML LSCs. Given
that TCR-MHC interactions are also not required,
Figure 7. CD4 and CD8-mediated GVL require intact T cell perforin or leukemia FADD/RIPK3,
a soluble factor is most likely responsible.
and T cell–derived IFN-γ alone is insufficient for GVL. Irradiated B6 mice were reconstituted with
We used Fadd–/– Ripk3–/– mBC-CML and
BALB/c BM and B6 Fadd–/– Ripk3–/– (DKO) or control B6 Fadd+/– Ripk3+/– mBC-CML (WT) with no
perforin–/– T cells to demonstrate that, despite
BALB/c T cells or with WT or perforin–/– CD8 cells (A) or CD4 cells (B). Data show survival rates from
1 of 2 similar experiments with 10 mice per group. P < 0.0003, comparing any WT or DKO BM-alone IFN-γ being critical for GVL, alone it is insufficient, as there was no GVL when T cells lacked
group with any WT T cell group. P > 0.07, comparing DKO BM-alone versus perforin–/– CD4 or CD8
groups. P values determined by 2-tailed Mann-Whitney U test.
perforin and leukemias lacked FADD and
RIPK3. These data also highlight the idea that
cytolytic pathways engaged by both CD4 and
CD8 cells are redundant, in that either perforin or death receptor
present results argue that GVL could be meaningfully augmented
FADD/RIPK3-dependent killing is sufficient for GVL.
by exposing malignant myeloblasts to IFN-γ after transplantation,
We studied models of CP-CML, BC-CML, and AML, which
timed to coincide with the presence of alloreactive cytolytic T cells.
share essential genetic and phenotypic features with their
The key translational question is how to achieve this. IFN-γ–induced
human counterparts (49). It will be important to determine
MHC upregulation and GVL sensitization do not require TCR-MHC
the importance of IFN-γ in GVL against other mouse myeloid
contacts between IFN-γ–producing T cells and leukemia cells (see
leukemias and against human AML samples. Available data
Figures 1 and 5). That is, IFN-γ can be delivered to leukemia cells in
suggest that IFN-γ could broadly impact GVL against human
trans by T cells that do not target the leukemia cells. This suggests
AML. Human AML stem cells include MHCII– cells (50), and
a feasible clinical strategy. CMV reactivation early after transplantation and the use of CMV seropositive donors have been associated
acute promyelocytic AML is classically MHCII–. Other leukewith lower rates of AML relapse (38–41). CMV reactivation induces
mias reported to be MHCII+ usually have cell populations that
+
the expansion of CMV-reactive T cells and NKG2C NK cells (42),
are MHCII–, as the MHCII expression threshold for calling an
both of which can produce IFN-γ and raise serum IFN-γ levels (43).
AML MHCII+ does not require all cells to express MHCII (51–
Although other explanations are possible, our data suggest that
54). Therefore, if alloreactive CD4 cells are to directly medianti-CMV immune responses could be promoting GVL through the
ate GVL against these MHCII– cells, MHCII expression must
elaboration of IFN-γ. Approaches to further promote the anti-CMV
be induced. Primary human AML cells and AML-like cell lines
immune response, perhaps by donor and recipient anti-CMV vacciexpress the IFN-γR and are IFN-γ responsive (48, 55–62), with
nation (44, 45), might augment GVL without an increase in GVHD.
both basal and IFN-γ–induced STAT1 phosphorylation (58) and
This strategy is analogous to our use of IFN-γ–positive CD8 cells to
MHCI and MHCII upregulation. We hope our results demonpromote GVL by IFN-γ–deficient CD4 cells.
strating a critical role for IFN-γ in GVL responses against two
That IFN-γ was required for CD4-mediated GVL is easy to
clinically relevant mouse models of myeloblastic leukemias
understand, given its importance in upregulating MHCII. Howwill both stimulate a broader evaluation of the IFN-γ responever, it was surprising that Ifngr–/– mBC-CML and MLL-AF9
siveness of additional mouse AML models and of human AML
specimens classified by molecular features, and the developmAML were resistant to CD8-mediated GVL, as these leukemias
ment of approaches to safely deliver IFN-γ in the clinic.
are MHCI+ at baseline, and IFN-γ–induced MHCI upregulation is
modest or does not occur in the case of MLL-AF9 AML. It is possible that MHCI upregulation crosses a threshold of MHCI-miHA
Methods
peptide complexes to sufficiently engage alloreactive T cells. However, the fact that Ifngr–/– mBC-CML was also resistant to CD8Mice
mediated GVL in the MHC-mismatched setting argues against this
C57BL6 (B6; H-2b) and BALB/c (H-2d) mice were purchased from
being the sole explanation, considering the much higher frequency
Harlan Laboratories. C3H.SW mice were purchased from The Jackjci.org   Volume 127   Number 7   July 2017
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son Laboratory and bred at Yale University. IFN-γ–deficient (63) and
perforin–/– mice backcrossed with BALB/c mice (64, 65) were bred at
the University of Iowa and at Yale University. Ifngr–/– mice were purchased from the Jackson Laboratory. Ifnar1–/– mice were obtained
from H. Rosenberg (66) (National Cancer Institute [NCI], Bethesda,
Maryland, USA) and bred at Yale University. Ifnar1–/– Ifngr–/– mice were
obtained from William Klimstra (University of Pittsburgh School of
Medicine, Pittsburgh, Pennsylvania, USA). Stat1–/– Stat2–/– mice were
obtained from John Alcorn (University of Pittsburgh). B6.H60 mice
were originally obtained from Derry Roopenian (The Jackson Laboratory) and were bred at the University of Pittsburgh. B6 Fadd–/– Ripk3 –/–
and control B6 Fadd–/+ Ripk3–/+ mice were maintained at St. Jude Children’s Research Hospital (Memphis, Tennessee, USA) (32).

TIB120; lab-prepared); CD117 phycoerythrin (PE) and Sca-1 FITC
(BD Pharmingen; clones 2B8 and Ly-6a/E); and anti-NGFR Alexa 647
(clone HB8737; lab-prepared). mBC-CML cells (lin–) could be identified by only staining for CD11b. Staining for Kb and I-A/I-E (MHCII)
was done with clones AF6-88.5 and M5/114.15.2, respectively (BioLegend). Phosphorylated STAT1 (p-STAT1) staining was performed with
or without IFN-γ stimulation, followed by fixation in 2% paraformaldehyde in PBS. The cells were permeabilized in BD Phosflow Perm Buffer
III for 30 minutes on ice, washed twice in BD Pharmingen Stain Buffer, and stained with PE-conjugated p-STAT1 antibody (pY701; BD).
H60-reactive T cells, which detect the LTFNYRNL peptide bound to
Kb, were identified by MHCI tetramer staining (TetH60+). H60 tetramers were created at the NIH’s tetramer facility (Atlanta, Georgia, USA).

Leukemia induction
mBC-CML and mCP-CML were created as previously described
(11, 12). Briefly, mBC-CML was created by spin-infection of BM
from 5FU-treated mice with two MSCV2.2-based retroviruses, one
expressing BCR-ABL (along with a truncated and nonsignaling
human nerve growth factor receptor [NGFR]) and a second expressing NUP98 and HOXA9 (coexpressing GFP) (11). MLL-AF9 AML
was induced by transduction with an MSCV2.2-based retrovirus
encoding the MLL-AF9 fusion cDNA and GFP (27) (gift of Scott Armstrong, Memorial Sloan Kettering Institute, New York, New York,
USA). Cells were passaged in vivo and frozen. For each experiment
mCP-CML was created by spin-infection with BCR-ABL retrovirus
alone as described previously (24).

Cell purifications
Lymph node (LN) and splenic cells were prepared as previously
described (11). T cell purifications were performed using EasySep negative selection reagents according to the manufacturer’s instructions
(STEMCELL Technologies). Cell purities were greater than 88%,
with less than 2% of contaminating CD4 or CD8 cells. CD8 memory
T cells were isolated from H60-vaccinated mice by first using a CD8
EasySep negative selection kit. Cells were then stained with antibodies against CD8 and CD44, followed by sorting on a FACSAria cell
sorter (BD Biosciences).

BMT
Four different strain pairings were used in alloBMT experiments. All
irradiation was delivered by a cesium irradiator. All BM was T cell
depleted and is referred to herein as BM.
C3H.SW (H-2b)→B6 (H-2b). B6 mice received 900 cGy irradiation
and were reconstituted with 5 × 106 to 7 × 106 C3H.SW BM, with or
without bead-purified C3H.SW CD4 or CD8 cells.
C3H.SW→B6.H60. B6.H60 mice received 900cGy irradiation
and were reconstituted with 7 × 106 C3H.SW BM cells and CD8+CD44+
cells from C3H.SW mice vaccinated against H60 as previously
described (26).
BALB/c (H-2d)→B6. B6 mice were irradiated (900 cGy) and
reconstituted with 107 BALB/c BM cells, with or without purified
BALB/c (WT or gene-deficient) CD4 or CD8 cells.
B6→BALB/c. Irradiated BALB/c mice (900 cGy) were reconstituted with 107 B6 BM cells, with or without purified B6 CD4 or CD8
cells. mBC-CML and AML cells were either from frozen stocks or
fresh cells harvested from sublethally irradiated B6 mice seeded 14 to
21 days beforehand. Two hundred micrograms anti-NK1.1 (PKC136;
lab-prepared) was given i.p. on days –2 and –1 in experiments with the
BALB/c→B6 strain pair and on days –2, –1, and +7 in experiments with
β2M–/– mBC-CML to prevent NK cell–mediated killing of MHCI– or
H-2d+b– cells.
Antibodies and flow cytometry
mCP-CML LSCs were identified by excluding lin+ cells using staining with biotin-conjugated antibodies against TER-119, Gr-1, CD19,
and CD11b (all from BD Pharmingen; clones TER-119, RB6-8C5,
1D3, and M1/70, respectively); CD4 and CD8 (clones GK1.5 and
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In vitro mBC-CML stimulation
Splenocytes from sublethally irradiated B6 mice injected with mBCCML cells approximately 2 to 3 weeks earlier (at least 80% EGFP+
NGFR+) were cultured for different lengths of time in DMEM with
10% FCS with graded amounts of IFN-γ (Peprotech). In experiments
in which IFN-γ was removed and cells were recultured, cells were
washed 4 times in 50 cc of media. The final supernatant was cultured
with fresh mBC-CML cells for another 72 hours as a confirmation that
IFN-γ had been removed. At the end of the culture period, cells were
more than 80% viable.
Gene expression profiling
mCP-CML. Irradiated BALB/c mice were reconstituted with B6 BM,
7 × 105 BCR-ABL spin-infected B6 BM (see leukemia induction) with
no B6 T cells, or with 5 × 105 B6 CD4 cells. On day 12 after BMT,
NGFR+ LSK cells were separately sorted from the spleens of 3 individual mice from each group.
mBC-CML. Irradiated B6 mice were reconstituted with C3H.
SW BM, B6 WT or Ifngr–/– mBC-CML, with no T cells, or with 4 × 106
C3H.SW CD4 cells. On day 14 after BMT, lin– mBC-CML cells were
sorted from the spleens of 3 individual mice from each group. RNA
was isolated using a QIAGEN RNA Extraction Kit, followed by library
preparation using an Epicentre kit. Expression was analyzed by quantitation using an Illumina WG-6 v2.0 Expression BeadChip. Differential expression was computed using the Bioconductor package (67),
and pathway analysis was performed using the limma “camera” function (68), which controls for intercorrelation among genes, and the
“canonical pathways” gene sets provided by mSigDB (69).
Statistics
Survival differences were calculated using the log-rank test (MantelCox) (GraphPad Prism; GraphPad Software version 7). In some
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CD8-mediated GVL against mCP-CML experiments, some mice
reached predetermined criteria for sacrifice due to GVHD. If spleens
were small and the most recent analysis of peripheral blood showed,
at most, only a few NGFR+ CP-CML cells, these mice were scored as
having GVHD and were censored (see Figure 2, G and H). Differences
in cell percentages were determined by 2-tailed Mann-Whitney U test.

Study approval
All animal studies were approved by the Yale University School
of Medicine IACUC and the University of Pittsburgh School of
Medicine IACUC.
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